awmsg logo



ceftolozane/tazobactam (Zerbaxa®)


Reference No. 2356

Publication date:
27/07/2016


Appraisal information

ceftolozane/tazobactam (Zerbaxa®) 1 g/0.5 g powder for concentrate for solution for infusion


Company: Merck Sharp & Dohme Ltd
BNF category: Infections
NMG meeting date: 08/06/2016
AWMSG meeting date: 13/07/2016
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 1716
Ministerial ratification: 26/07/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Ceftolozane/tazobactam (Zerbaxa®) is recommended as an option for restricted use within NHS Wales for the treatment of the following infections in adults: complicated intra-abdominal infections; acute pyelonephritis; and complicated urinary tract infections. Ceftolozane/tazobactam (Zerbaxa®) is recommended only following non responsive first line therapy due to resistance, i.e. where susceptibility has been confirmed and ceftolozane/tazobactam (Zerbaxa®) is considered the most clinically appropriate option following Consultant Microbiologist advice. Ceftolozane/tazobactam (Zerbaxa®) is not recommended for use within NHS Wales outside of this subgroup of patients. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download